ViaCyte ^Private

ViaCyte is a preclinical therapeutic company that focuses on regenerative medicine therapies for diabetes. Their main goal is to develop a product that can free both Type 1 and Type 2 diabetes patients from insulin dependence on a long-term basis. They achieve this through the differentiation of stem cells into pancreatic beta-cell precursors, which are then implanted subcutaneously in an encapsulation device. Their therapy has shown promising results in producing therapeutically relevant levels of insulin in response to blood glucose, and sustaining diabetic animals. ViaCyte's ultimate aim is to reduce or eliminate hypoglycemic, microvasculature, and weight-related cardiovascular complications associated with diabetes.